Spyre Therapeutics, Inc. presented new data on SPY002, a potential anti-TL1A agent for Inflammatory Bowel Disease at the UEGW Congress. Results show SPY002 is well tolerated and can be dosed quarterly or twice-yearly. Preclinical data also demonstrated superior efficacy in combination programs for IBD treatment. Spyre Therapeutics is a biotechnology company focusing on IBD and immune-mediated diseases with investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23. The company aims to create next-generation therapies through antibody engineering and rational therapeutic combinations. For more information, visit http://spyre.com.

Read more at GlobeNewswire: Spyre Therapeutics Announces Poster Presentations at United